• CHMP adopts negative opinion over osteoporosis drug Evenity

    The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has refused to recommend approval for Amgen and UCB’s Evenity (romosozumab) for the treatment of severe osteoporosis.

    The agency said that as the benefits of Evenity did not outweigh its risks, it recommended refusal of the drug’s marketing authorization.

    The marketing authorization application (MAA) of the drug was based on the findings of a large development programme, which included three phase 3 studies among others, which featured close to 12,000 patients.

    Evenity was recently approved by the US Food and Drug Administration (FDA) for the treatment of osteoporosis in postmenopausal women at high risk for fracture.

    CHMP said that its negative opinion was due to results suggesting that patients subjected to the drug had an increased risk of serious effects on the heart or circulatory system, including heart attacks or strokes.

    Apart from that, CHMP said that when all the findings of the drug’s clinical development were looked at together, there were more deaths in patients aged more than 75 years who were subjected to the medicine.

    The agency further said that as it was not clear why the drug seemed to increase the risk of heart and circulatory problems, and why there was no obvious group of patients in whom the risk of these was lower. As a result, the agency said that measures to lower the risk could not be readily put in place.

    CHMP said that although Evenity was effective in lowering the risk of fracture in patients with severe osteoporosis, its benefit was not so convincing in those with less severe disease.

    EMA: Refusal of the marketing authorization for Evenity (romosozumab)

     

    Πηγή

    https://www.pharmaceutical-business-review.com/news/chmp-evenity-negative-opinion/

  • ΕΝΗΜΕΡΩΣΗ

    Με αφορμή γραπτού ερωτήματος του συναδέλφου ορθοπαιδικού Κου Αθανάσιου Σιδηρόπουλου και πολλών άλλων συναδέλφων καθώς και προφορικών διευκρινιστικών ερωτημάτων, το Ελληνικό Ίδρυμα Οστεοπόρωσης (ΕΛ.Ι.ΟΣ.) που αποβλέπει στην καλύτερη αντιμετώπιση των Μεταβολικών Νοσημάτων των Οστών και στηριζόμενο πάντα μόνο σε επιστημονικά κριτήρια βάσει των διεθνών και ελληνικών οδηγιών (ΕΛ.Ι.ΟΣ., Ε.Ε.Μ.Μ.Ο.), προσκαλεί και ενθαρρύνει τα μέλη του και όλους τους επιστήμονες με ενασχόληση στο μεταβολισμό των οστών να απευθύνονται στο ΕΛΙΟΣ, τόσο για τους επιστημονικούς προβληματισμούς σχετικά με την καλύτερη διαχείριση των νοσημάτων, όσο και για θέματα που άπτονται σε καθημερινά ζητήματα και στην καθημερινή γενική πρακτική.

     

    Για το Διοικητικό Συμβούλιο του ΕΛΙΟΣ

    Γεώργιος Καπετάνος

    Ομότιμος Καθηγητής Ορθοπαιδικής ΑΠΘ

    Πρόεδρος ΕΛΙΟΣ

  • FDA Approves Evenity

    April 9, 2019 

    The U.S. Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). These are women with a history of osteoporotic fracture or multiple risk factors for fracture, or those who have failed or are intolerant to other osteoporosis therapies.

    More than 10 million people in the U.S. have osteoporosis, which is most common in women who have gone through menopause. People with osteoporosis have weakened bones that are more likely to fracture.

    “Today’s approval provides women with postmenopausal osteoporosis who are at high risk of fracture with a new treatment that will reduce this risk,” said Hylton V. Joffe, M.D, M.M.Sc., director of the Center for Drug Evaluation and Research’s Division of Bone, Reproductive and Urologic Products. “But Evenity may increase the risk of heart attack, stroke and cardiovascular death so it’s important to carefully select patients for this therapy, which includes avoiding use in patients who have had a heart attack or stroke within the previous year.”

    Evenity is a monoclonal antibody that blocks the effects of the protein sclerostin and works mainly by increasing new bone formation. One dose of Evenity consists of two injections, one immediately following the other, given once a month by a health care professional. The bone forming effect of Evenity wanes after 12 doses so more than 12 doses should not be used. If osteoporosis therapy is needed after the 12 doses, patients should begin an osteoporosis treatment that reduces bone breakdown.

    The safety and efficacy of Evenity were demonstrated in two clinical trials involving a total of more than 11,000 women with postmenopausal osteoporosis. In the first trial, one year of treatment with Evenity lowered the risk of a new fracture in the spine (vertebral fracture) by 73% compared to placebo. This benefit was maintained over the second year of the trial when Evenity was followed by one year of denosumab (another osteoporosis therapy) compared to placebo followed by denosumab. In the second trial, one year of treatment with Evenity followed by one year of alendronate (another osteoporosis therapy) reduced the risk of a new vertebral fracture by 50% compared to two years of alendronate alone. Evenity followed by alendronate also reduced the risk of fractures in other bones (nonvertebral fractures) compared to alendronate alone.

    Evenity increased the risk of cardiovascular death, heart attack and stroke in the alendronate trial, but not in the placebo trial. Therefore, Evenity contains a boxed warning on its labeling stating that it may increase the risk of heart attack, stroke and cardiovascular death and should not be used in patients who have had a heart attack or stroke within the previous year. Health care professionals should also consider whether the benefits of Evenity outweigh its risks in those with other risk factors for heart disease and should discontinue Evenity in any patient who experiences a heart attack or stroke during treatment.

    Common side effects of Evenity included joint pain and headache. Injection site reactions were also observed.

    The FDA granted the approval of Evenity to Amgen.

    Source: FDA

seractil 1016x130

Αποτελέσματα προηγούμενων δημοσκοπήσεων

Δ 5 Δ 4

 Δ 1Δ 2Δ 3

 

Δ 8

 

Δ 9